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ABSTRACT
Objective: The objective of this study was to analyze the distribution of non-alcoholic fatty liver disease (NAFLD) with reference to age, gender, and 
socioeconomic status, to look for clinical features, anthropometric measurements, and biochemical parameters in patients of NAFLD, and to analyze 
statistically significant differences in biochemical parameters of lean, overweight, and obese NAFLD patients, in a medical college hospital of Durgapur.
Methods: This was a prospective, cross-sectional hospital-based study carried out over 2 months. Patients diagnosed as NAFLD based on clinical 
findings and ultrasonography (USG) were evaluated. Patients were classified on the basis of body mass index (BMI) and their fibrosis score calculated.
Results: The authors report several interesting findings that warrant further exploration. In this study, average age was 42 years and there was a male 
preponderance. 31.25% among patients who had undergone USG evaluation were diagnosed as NAFLD. Glucose, glycosylated hemoglobin, thyroid-
stimulating hormone (TSH), BMI, and lipid profile were significantly different in controls and cases. In NAFLD patient group, 48% were lean, 40% 
overweight, and 12% obese. Lean patients had significantly different alanine transaminase/aspartate transaminase, TSH, and fibrosis score compared 
to overweight and obese patients.
Conclusion: Authors stress on the importance of early identification of patients and stratifying them using less invasive, highly accurate, and affordable 
screening tools such as USG, biochemical tests, and fibrosis scores. More large-scale prospective studies can validate our observations, help physicians 
in early identification of patients who may benefit from therapeutic interventions, and even help them formulate more effective treatment algorithms.
Keywords: Non-alcoholic fatty liver disease, Fatty liver, Steatohepatitis, Metabolic syndrome, Fibrosis score.
INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of 
liver disease in the Western world [1]. The spectrum of abnormalities 
includes a simple accumulation of triglycerides (TG) in the 
hepatocytes (hepatic steatosis), hepatic steatosis with inflammation 
(steatohepatitis), fibrosis, and cirrhosis. The prevalence of NAFLD 
is around 9–32% in the general Indian population [2]. It is present 
in up to 90% of obese patients [3]. NAFLD is also the most common 
cause of elevated liver enzymes [4]. It can progress to hepatitis and 
hepatocarcinoma. Understanding the epidemiology and possible 
correlations of dyslipidemia, glycemic status and other risk factors with 
NAFLD are essential for developing effective treatment and prevention 
strategies, especially for people of this part of eastern India.
Hence, this study was undertaken to evaluate the risk factors and 
biochemical characteristics of NAFLD with the aim to analyze the 
distribution of NAFLD with reference to age, gender, and socioeconomic 
status, to look for clinical features, anthropometric measurements, 
and biochemical parameters in patients of NAFLD, and to analyze 
statistically significant differences in biochemical parameters of 
patients and controls. Such a study has not been documented in this 
part of West Bengal.
METHODS
This was a prospective, cross-sectional hospital-based study carried 
out over 2 months. 160 patients had undergone ultrasonographic 
examination of the liver from medicine and gastroenterology outpatient 
department (OPD) of a tertiary care teaching hospital. 50 patients 
diagnosed as NAFLD by ultrasonography (USG) criteria were taken 
up for study. Patients were evaluated on history, clinical examination, 
anthropometric measurements, biochemical test, and USG of the 
abdomen. 30 age- and sex-matched healthy subjects from staff and 
students of medical college and hospital were taken as control group.
In this study, out of about 375 patients who presented to gastroenterology 
OPD for various complaints, 160 patients with elevated liver enzymes 
had undergone ultrasonographic study of liver, of which 50 patients 
had been diagnosed as NAFLD. Following patients were included in the 
study: NAFLD patients diagnosed with USG, patient without a history 
of alcohol consumption of more than 30 g/day for men and 20 g/
day for women, and no other existing causes of chronic liver disease. 
Subjects with any of the following were excluded: Positive serum level 
for hepatitis B surface antigen (using enzyme-linked immunosorbent 
assay [ELISA], Enzygnost, Siemens); positive serum level for hepatitis 
C virus antibody (using ELISA), alcohol use more than 20 g/day; and 
active malignancy, history of chronic liver diseases including Wilson’s 
disease, hemochromatosis, and autoimmune hepatitis, and history of 
use of drugs causing liver function abnormality (hepatotoxic drugs such 
as tamoxifen, amiodarone, and methotrexate).
Consent for including data for the purpose of the study was obtained 
from each patient at the time of enrolment. The study protocol was 
approved by the Institutional Ethics Committee. Patient selection 
criteria were based on Dowman et al. [1].
Monthly income as indicator of socioeconomic status was recorded as 
follows: Upper socioeconomic status - 30,000/- and above per month, 
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middle socioeconomic status - 10,000–30,000/- per month, and lower 
socioeconomic status - <10,000/- per month. Background was recorded 
as urban or rural.
Weight, height, waist circumference (WC), and blood pressure (BP) 
including systolic BP (SBP) and diastolic BP (DBP) were measured. 
Body mass index (BMI) was calculated according to the World Health 
Organization (WHO) [5]. Lean patients had BMI 18.5–24.9 kg/m2, 
overweight patients had BMI 25–29.9 kg/m2, and obese had a BMI 
>30 kg/m2.
Waistline was measured at midpoint between lower chest wall and 
iliac crest with the patient standing. WC >90 cm in male and >80 cm in 
female would indicate central obesity.
NAFLD was diagnosed by USG of liver using the standardized criteria 
of increased echogenicity of liver texture compared to the right kidney, 
lack of transmission of sound to the posterior diaphragmatic interface, 
lack of visibility of vascular structure due to ill-defined portal walls 
invaded by fat, and increased liver size as measured in midclavicular 
line [6]. Fatty liver was diagnosed in the presence of two of the three 
observations of bright hepatic echotexture compared to kidney and 
spleen, blurring of hepatic veins, and loss of deep echodiscontinuous 
diaphragm.
All respondents donated blood samples after over 10 h of overnight 
fasting for biochemical measurement including fasting blood 
glucose, total cholesterol (TC), high-density lipoprotein cholesterol 
(HDL-C), low-density lipoprotein cholesterol (LDL-C), TG, aspartate 
aminotransferase (AST), alanine aminotransferase (ALT), γ-glutamyl 
transferase, alkaline phosphatase, and C-reactive protein (Siemens 
Dimension RXL Max Biochemistry Analyzer). Other tests done were 
complete blood count (Sysmex KX 21), prothrombin time (Sysmex 
CA50 Analyzer), serology for antinuclear antibody, markers for viral 
hepatitis A, B, C, and E by ELISA, serum ferritin, ceruloplasmin, thyroid-
stimulating hormone (TSH) (chemiluminescence, immunoassay on 
Siemens Advia Centaur XP), and glycosylated hemoglobin (HbA1C) by 
HPLC (Transasia Hb Vario).
We have used NAFLD fibrosis score (www.nafld score.com) which 
is a validating scoring system comprising of six parameters (age, 
hyperglycemia, BMI, platelet count, albumin, and AST/ALT ratio). This 
helps to classify patients into groups with low, intermediate, and high 
probability/risk for liver-related complications [7].
All values are reported as the mean and standard deviation for 
continuous variables and the number (percent) for categoric variables. 
Comparison of groups was performed using analysis of variance and 
Fisher tests. Statistical significance was set at p<0.05. All statistical 
calculations were performed using Microsoft Excel.
RESULTS AND DISCUSSION
With the increased incidence of diabetes mellitus, obesity, and insulin 
resistance in India in the past two decades, it is only logical to expect an 
increase in the incidence of NAFLD in India. Several diagnostic modalities 
have been used for the diagnosis of fatty liver, including ultrasound, 
liver enzymes, computed tomography, magnetic resonance imaging 
spectroscopy (MRS), and liver biopsy. Ultrasound was the preferred 
method for our study due to the relatively low cost, fair accuracy, and non-
invasive nature. Liver enzymes may not be elevated in NAFLD patients. 
Liver biopsy through the gold standard is not feasible in all suspected 
cases. The accuracy of MRS is overshadowed by its huge cost.
In this study, 31.25% of 160 patients who had undergone USG evaluation 
were diagnosed as NAFLD. About two-third (62%) patients were from 
rural areas. 62% of NAFLD patients were middle socioeconomic class. 
Our study shows that weight and BMI were significantly higher in cases 
compared to controls (p<0.05). Mean age of the patients is 42 years. 
More males were affected as has been depicted in Table 1.
We classified cases and controls into lean, overweight, and obese with 
BMI ranging 18.5–25 kg/m2 for lean, 25–30 kg/m2 for overweight, 
and >30 kg/m2 for obese [5]. In the control group, 77% were lean, 
20% overweight, and 3% obese. In NAFLD patient group, 48% were 
lean, 40% overweight, and 12% obese. Lean and overweight together 
constituted 88% of the total patient population.
Our study shows that lipid profile was significantly higher in cases 
compared to controls. Mean TSH is significantly higher among cases 
when compared with that of control group. Mean serum glucose level 
is significantly higher among cases. All these biochemical findings are 
summarized in Table 2.
Mean total serum cholesterol, triglyceride, and LDL cholesterol level of 
control group were significantly lower than patient group. A study [8] 
showed significant association of elevated total serum cholesterol and 
NAFLD as when compared with controls. However, other authors [9,10] 
showed no significant association of total serum cholesterol and NAFLD. 
Singh et al. [11] found that serum triglyceride level was significantly 
higher in NAFLD group when compared to controls. Nigam et al. [12] 
showed significant association of serum triglyceride level and NAFLD. 
Mean serum HDL level is low among NAFLD patients when compared 
with control group, and this is statistically significant (p<0.005). Odds 
ratio as per another study [13] of low HDL-C (<40 mg/dl in men or 
<50 mg/dl in women) is 1.61–2.0. Although most patients of NAFLD 
are obese or overweight, lean NAFLD may represent a different 
pathophysiology, rather than merely a by-product of different 
BMI [14]. Our lean patients’ lipid profile did not differ significantly from 
overweight and obese patients.
As per a study [15], the entire histologic spectrum of NAFLD can 
be seen in subjects with normal ALT. Our study, like others’ [12,16], 
showed a significant association of ALT with NAFLD. However, the 
study of Gupte et al. [17] showed no significant association between 
the two.
Table 1: Anthropometric measurement of cases and controls 
(mean±SD)
Parameter Control (n=30) Case (n=50) p value
Age 31.2±8.8 42±12 NS
Sex (M/F) 21/9 30/20
Height (m) 1.7±0.1 1.7±0.1 NS
Weight (kg) 67.8±10.5 70.5±15.4 <0.05
BMI (Kg/m2) 23.6±2.9 25.6±4 <0.05
Waist/hip ratio 0.9±0.1 0.9±0.3 NS
NS: Not significant, BMI: Body mass index
Table 2: Biochemical characteristics in cases and controls 
(Mean±SD)
Parameter Control (n=30) Case (n=50) p value
Cholesterol (mg/dl) 151.4±18 181.2±46 p<0.001
Triglyceride (mg/dl) 115±17.4 147.4±56.7 p<0.005
HDL cholesterol (mg/dl) 49.9±7.7 43.3±10.5 p<0.005
LDL cholesterol (mg/dl) 78.7±10.1 98.1±30.9 p<0.001
AST (U/L) 21.8±8 46.6±22.7 NS
ALT (u/l) 30±8.2 87.7±51.5 p<0.05
Albumin (g/dl) 4.3±0.2 4.3±0.5 NS
TSH (mIU/L) 2.3±1.2 3.6±1.9 p<0.001
Fasting glucose (mg/dl) 102±5.7 115.2±45 p=0.001
Ferritin (ng/ml) 117.6±87.3 146.7±97.3 NS
Ceruloplasmin (mg/dl) 26±4.2 30.4±6.4 NS
HBA1C (%) 4.9±0.5 5.0±0.9 p=0.001
Platelet (103/mm3) 2.9±0.7 3.1±1 NS
HBA1C: Hemoglobin, TSH: Thyroid-stimulating hormone, ALT: Alanine 
aminotransferase, AST: Aspartate aminotransferase, LDL: Low-density 
lipoprotein, HDL: High-density lipoprotein
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Plasma glucose level and HBA1C were higher among NAFLD cases 
when compared with control group, as were observed by other 
authors [16,18-21]. Mean HBA1C level in our study was 4.9±0.5 among 
control group and 4.8±0.9 among NAFLD cases. When we divided 
the patient group into lean, overweight, and obese as per the WHO 
classification, we found that HDL-C was significantly different in obese 
compared to lean. AST/ALT ratios were significantly different on 
comparing lean with overweight and lean with obese.
In a recent study [22], it was observed that BMI, SBP, DBP, TC, HDL 
cholesterol, LDL cholesterol, and triglyceride were significantly different 
in lean patients with NAFLD compared to control group. Furthermore, 
WC in men and hip circumference in women were higher in lean patients 
with NAFLD. Feng et al. [23] noted that total free fatty acid (FFA) profiles 
were insignificantly different between lean (2093.33±558.11 µg/ml) 
and overweight (2420.81±555.18 µg/ml) NAFLD patients, obese NAFLD 
(2739.01±810.35 µg/ml) presented most significantly elevated 
(p<0.05) total FFA profiles.
Obesity is known to be a good predictor of hepatic steatosis and 
disease progression [24]. Steatosis is at least 2 times more frequent in 
overweight than in lean subjects. The lipids which are elevated inside 
the hepatocytes may be TG, FFA, diacylglycerol, cholesterol, cholesterol 
esters, phospholipids, and ceramides. In a study in India [25], it was 
reported that a statistically significant difference between the BMI, 
waist–hip ratio, mean triglyceride, and AST and ALT values exists 
between the obese and non-obese patients of NAFLD.
In Table 3, the mean values of various parameters in 24 lean, 20 
overweight, and 6 obese patients are shown. Weight difference between 
overweight and obese was statistically significant. HDL cholesterol 
levels were significantly different in obese and lean patients. AST/ALT 
ratio was statistically significant on comparing lean with obese and 
again on comparing lean with overweight. TSH was significantly 
different in lean compared to overweight and also lean compared to 
obese.
The adipose tissues of lean NAFLD patients may have more pro-
inflammatory potential. In lean NAFLD patients, visceral adipocytes’ 
cytokine secretion and small intestinal bacterial overgrowth and the 
resulting endotoxemia have been shown to be the culprits [14].
TSH levels showed statistically significant difference when we compared 
lean with overweight and lean with obese patients. The thyroid gland 
is significantly involved in energy homeostasis, lipid and carbohydrate 
metabolism, and adipogenesis. In a clinical setting, subclinical 
hypothyroidism has been associated with metabolic syndrome, 
cardiovascular mortality, and disturbance of lipid metabolism. The 
prevalence of hypothyroidism was reported to a range from 15.2% to 
36.3% [26] among patients with NAFLD or non-alcoholic steatohepatitis.
To clarify the mechanism of thyroid dysfunction and NAFLD, studies 
mention elevated leptin and visfatin, both adipocytokines seen in 
NAFLD [27]. Leptin is involved in the regulation of appetite. Elevated 
levels are seen in obesity. They induce collagen synthesis in the liver 
and stimulate hepatic insulin resistance [28]. Patients with NAFLD have 
abnormal lipid profiles. Thyroid hormones induce their effects on lipid 
metabolism through thyroid hormone receptor β, which is expressed in 
liver [29]. Thyroid hormone receptor activation results in a reduction in 
body weight and fat as well as a decrease in cholesterol and triglyceride 
levels, which takes place only in hepatocytes [30,31]. Stress also elevates 
leptin levels and can be an indirect cause for NAFLD. While one study [32] 
advocates the use of Ezenus in the treatment of stress, another study [33] 
mentions that flavonoids present in Vitis Vinifera seeds have powerful 
antioxidant and anti-inflammatory properties, maintain hepatocytes 
structure integrity, and decrease ALT levels in NAFLD.
In our study, we also used the fibrosis score as a risk assessment for 
NAFLD patients developing complications of fibrosis, which has been 
depicted in Fig. 1.
In Fig. 1, we found that 70% of patients had NAFLD score <1.5. They 
are at low probability of progressing to liver fibrosis. 10% of NAFLD 
patients had a score >0.67 and were at high probability of progressing 
to fibrosis while 20% of patients with score ranging from >1.5 to <0.67 
are at intermediate probability of progressing to liver fibrosis [7]. 
Compared to lean patients, overweight and obese showed significantly 
higher fibrosis score (p<0.05).
Table 3: Comparison of anthropometric and biochemical parameters between lean overweight and obese patients
Parameter Lean [1] Overweight [2] Obese [3] p value between 1 and 2 p value between 2 and 3 p value between 1 and 3
Age (years) 40±11.4 45.3±11.8 35.8±11.5 NS NS NS
Sex (M:F) 13:11 12:08 04:02 NS NS NS
Height (m) 1.6±0.1 1.7±0.1 1.7±0.1 NS NS NS
Weight (kg) 60.6±7.5 75.8±9.2 92.4±24.2 NS p<0.05 NS
BMI (kg/m2) 22.3±1.4 27.3±1.4 33.1±3.2 NS NS NS
Waist/hip ratio 0.9±0.2 0.9±0.4 0.8±0.5 NS NS NS
Cholesterol (mg/dl) 171.1±40.6 194.9±53.5 176.5±31.6 NS NS NS
Triglyceride (mg/dl) 141.7±55.4 151.4±63.2 157.3±43.3 NS NS NS
HDL cholesterol (mg/dl) 41±8.8 43.7±11.6 51.3±10.7 NS NS p<0.05
LDL cholesterol (mg/dl) 93.1±29.6 105.1±33 94.7±29 NS NS NS
AST (U/L) 49.7±22.3 38.1±15.2 62.5±35.6 NS p<0.05 NS
ALT (U/L) 103.6±56.4 67.5±41.5 91.5±44.3 NS NS NS
AST/ALT 0.5±0.2 0.7±0.3 0.7 0.2 p<0.05 NS p<0.05
Albumin (g/dl) 4.2±0.5 4.3±0.5 4.4±0.4 NS NS NS
TSH (mIU/L) 3±1.2 4.1±2.4 4.2±2.5 p<0.05 NS p<0.05
Glucose (mg/dl) 120.3±54.1 116.3±30.9 114.3±46 NS NS NS
Ferritin (ng/mL) 132.6±59.9 175.8±123.5 161.4±113.1 NS NS NS
Ceruloplasmin (mg/dL) 30.5±6.7 29.7±6.6 32.5±5.5 NS NS NS
HBA1C (%) 4.7±1 5.2±1.1 5.6±0.8 NS NS NS
Platelet (103/mm3) 3±0.9 3.2±1 3.3±0.8 NS NS NS
HBA1C: Hemoglobin, TSH: Thyroid-stimulating hormone, ALT: Alanine aminotransferase, AST: Aspartate aminotransferase, LDL: Low-density lipoprotein, 
HDL: High density lipoprotein, NS: Not significant
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CONCLUSION
Obesity, insulin resistance, and metabolic syndrome prevalence are 
continuously increasing. This has grave implications because the 
resultant increase in NAFLD patients will translate into increased 
numbers of patients with complications such as cirrhosis, liver failure, 
and hepatocellular carcinoma. Here lies the importance of early 
identification of the disease using less invasive,highly accurate and 
affordable screening tools, like USG and biochemical tests.More large-
scale prospective studies can validate our observations, help physicians 
in early identification of patients who may benefit from therapeutic 
interventions, and even help them formulate more effective treatment 
algorithms.
ACKNOWLEDGMENT
This was done under ICMR STS Project for MBBS students.
AUTHORS’ CONTRIBUTIONS
ML designed the study, wrote the protocol, and wrote the first draft of 
study; ND collected data and did data analysis; DM helped in patient 
selection and diagnosis, assisted with data collection. BB helped in 
patient selection and diagnosis, assisted with data collection. BG 
performed the literature searches and wrote the final draft. All authors 
read, provided critical inputs, and approved the final manuscript.
CONFLICTS OF INTEREST
The authors declared that they have no conflicts of interest.
REFERENCES
1. Dowman JK, Tomlinson JW, Newsome PN. Systematic review: The 
diagnosis and staging of non-alcoholic fatty liver disease and non-
alcoholic steatohepatitis. Aliment Pharmacol Ther 2011;33:525-40.
2. Kalra S, Vithalani M, Gulati G, Kulkarni CM, Kadam Y, Pallivathukkal J, 
et al. Study of prevalence of nonalcoholic fatty liver disease (NAFLD) 
in type 2 diabetes patients in India (SPRINT). J Assoc Physicians India 
2013;61:448-53.
3. Barros F, Setúbal S, Martinho JM, Ferraz L, Gaudêncio A. Correlation 
of non-alcoholic fatty liver disease and features of metabolic syndrome 
in morbidly obese patients in the preoperative assessment for bariatric 
surgery. Arq Bras Cir Dig 2016;29:260-3.
4. Vernon G, Baranova A, Younossi ZM. Systematic review: The 
epidemiology and natural history of non-alcoholic fatty liver disease 
and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 
2011;34:274-85.
5. World Health Organization. Obesity: Preventing and Managing the 
Global Epidemic Report of a WHO Consultation (WHO Technical 
Report Series 894); 2000. p. 9.
6. Farrell GC, Chitturi S, Lau GK, Sollano JD, Asia-Pacific Working 
Party on NAFLD. Guidelines for the assessment and management of 
non-alcoholic fatty liver disease in the Asia-pacific region: Executive 
summary. J Gastroenterol Hepatol 2007;22:775-7.
7. Treeprasertsuk S, Björnsson E, Enders F, Suwanwalaikorn S, 
Lindor KD. NAFLD fibrosis score: A prognostic predictor for mortality 
and liver complications among NAFLD patients. World J Gastroenterol 
2013;19:1219-29.
8. Mahaling DU, Basavaraj MM, Bika AJ. Comparison of lipid profile 
in different grades of non-alcoholic fatty liver disease diagnosed on 
ultrasound. Asian Pac J Trop Biomed 2013;3:907-12.
9. Abangah G, Yousefi A, Asadollahi R, Veisani Y, Rahimifar P, 
Alizadeh S, et al. Correlation of body mass index and serum parameters 
with ultrasonographic grade of fatty change in non-alcoholic fatty liver 
disease. Iran Red Crescent Med J 2014;16:e12669.
10. Agarwal R, Mishra S, Dixit VK, Rai S. Non alcoholic fatty liver disease 
and metabolic syndrome. Indian J Prev Soc Med 2011;42:2-3.
11. Singh SP, Singh A, Misra D, Misra B, Pati GK, Panigrahi MK, et al. 
Risk factors associated with non-alcoholic fatty liver disease in Indians: 
A case-control study. J Clin Exp Hepatol 2015;5:295-302.
12. Nigam P, Bhatt SP, Misra A, Vaidya M, Dasgupta J, Chadha DS, et al. 
Non-alcoholic fatty liver disease is closely associated with sub-clinical 
inflammation: A case-control study on Asian Indians in north India. 
PLoS One 2013;8:e49286.
13. Mohan V, Farooq S, Deepa M, Ravikumar R, Pitchumoni CS. 
Prevalence of non-alcoholic fatty liver disease in urban south Indians 
in relation to different grades of glucose intolerance and metabolic 
syndrome. Diabetes Res Clin Pract 2009;84:84-91.
14. Kumar R, Mohan S. Non-alcoholic fatty liver disease in lean subjects: 
Characteristics and implications. J Clin Transl Hepatol 2017;5:216-23.
15. Mofrad P, Contos MJ, Haque M, Sargeant C, Fisher RA, Luketic VA, 
et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease 
associated with normal ALT values. Hepatology 2003;37:1286-92.
16. Ghamar-Chehreh ME, Khedmat H, Amini M, Taheri S. Predictive 
factors for ultrasonographic grading of nonalcoholic fatty liver disease. 
Hepat Mon 2012;12:e6860.
17. Gupte P, Amarapurkar D, Agal S, Baijal R, Kulshrestha P, Pramanik S, 
et al. Non-alcoholic steatohepatitis in Type 2 diabetes mellitus. 
J Gastroenterol Hepatol 2004;19:854-8.
18. Bellentani S, Tiribelli C, Saccoccio G, Sodde M, Fratti N, De Martin C, 
et al. Prevalence of chronic liver disease in the general population of 
northern Italy: The dionysos study. Hepatology 1994;20:1442-9.
19. Yano E, Tagawa K, Yamaoka K, Mori M. Test validity of periodic liver 
function tests in a population of Japanese male bank employees. J Clin 
Epidemiol 2001;54:945-51.
20. Su CC, Wang K, Hsia TL, Chen CS, Tung TH. Association of 
nonalcoholic fatty liver disease with abnormal aminotransferase and 
postprandial hyperglycemia. J Clin Gastroenterol 2006;40:551-4.
21. Ma H, Xu C, Xu L, Yu C, Miao M, Li Y, et al. Independent association 
of hbA1c and nonalcoholic fatty liver disease in an elderly Chinese 
population. BMC Gastroenterol 2013;13:3.
22. Naderian M, Kolahdoozan S, Sharifi AS, Garmaroudi G, Yaseri M, 
Poustchi H, et al. Assessment of lean patients with non-alcoholic fatty 
liver disease in a middle income country; prevalence and its association 
with metabolic disorders: A cross-sectional study. Arch Iran Med 
2017;20:211-7.
23. Feng R, Luo C, Li C, Du S, Okekunle AP, Li Y, et al. Free fatty 
acids profile among lean, overweight and obese non-alcoholic 
fatty liver disease patients: A case control study. Lipids Health Dis 
2017;16:165.
24. Machado MV, Cortez-Pinto H. Non-alcoholic fatty liver disease: What 
the clinician needs to know. World J Gastroenterol 2014;20:12956-80.
25. Patell R, Dosi R, Joshi H, Sheth S, Shah P, Jasdanwala S, et al. Non-
alcoholic fatty liver disease (NAFLD) in obesity. J Clin Diagn Res 
2014;8:62-6.
26. Eshraghian A, Hamidian Jahromi A. Non-alcoholic fatty liver disease 
and thyroid dysfunction: A systematic review. World J Gastroenterol 
2014;20:8102-9.
27. Chung GE, Kim D, Kim W, Yim JY, Park MJ, Kim YJ, et al. Non-
alcoholic fatty liver disease across the spectrum of hypothyroidism. 
J Hepatol 2012;57:150-6.
28. Oswal A, Yeo G. Leptin and the control of body weight: A review 
of its diverse central targets, signaling mechanisms, and role in the 
pathogenesis of obesity. Obesity (Silver Spring) 2010;18:221-9.
29. Hulbert AJ. Thyroid hormones and their effects: A new perspective. 
Biol Rev Camb Philos Soc 2000;75:519-631.
30. Grover GJ, Mellström K, Ye L, Malm J, Li YL, Bladh LG, et al. 
Selective thyroid hormone receptor-beta activation: A strategy for 
reduction of weight, cholesterol, and lipoprotein (a) with reduced 
cardiovascular liability. Proc Natl Acad Sci U S A 2003;100:10067-72.
31. Erion MD, Cable EE, Ito BR, Jiang H, Fujitaki JM, Finn PD, et al. 
Targeting thyroid hormone receptor-beta agonists to the liver reduces 
Fig. 1: Non-alcoholic fatty liver disease fibrosis score as an 
indicator of the probability of fibrosis in patients
505
Asian J Pharm Clin Res, Vol 12, Issue 1, 2019, 501-505
 Lodh et al. 
cholesterol and triglycerides and improves the therapeutic index. Proc 
Natl Acad Sci U S A 2007;104:15490-5.
32. Khandelwal VK, Singh P, Ravingerova T, Chaudhary M. Evaluation 
of Ezenus in an experimental model of diet-induced alcoholic and 
non-alcoholic fatty liver condition in rats. Int J Pharm Pharm Sci 
2016;7:247-52.
33. Ahmed HH, Salem AM, Mohamed MR, Shahat AA, Khalil WK, 
Mohamed SH. Experimental evidences for the promising therapeutic 
role of Vitis vinifera seed extract against nonalcoholic steatohepatitis. 
Int J Pharm Pharm Sci 2015:7:417-24.
